{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:55:03Z","timestamp":1792234503050,"version":"4.4.0"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2024,10,22]]},"abstract":"\n Importance<\/jats:title>\n Although patients with myocarditis after COVID-19 mRNA vaccination appear to have a good prognosis near hospital discharge, their longer-term prognosis and management remain unknown.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To study the cardiovascular complications of post\u2013COVID-19 mRNA vaccination myocarditis and other types of myocarditis during an 18-month follow-up, as well as disease management based on a study of the frequency of medical procedures and drug prescriptions.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n In this cohort study based on the French National Health Data System, all individuals aged 12 to 49 years hospitalized for myocarditis in France between December 27, 2020, and June 30, 2022, were identified.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Individuals were categorized as having postvaccine myocarditis (within 7 days after COVID-19 mRNA vaccine), post\u2013COVID-19 myocarditis (within 30 days of SARS-CoV-2 infection), or conventional myocarditis.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The occurrence of clinical outcomes (hospital readmission for myopericarditis, other cardiovascular events, all-cause death, and a composite outcome of these events) over the 18 months following hospital admission were analyzed using weighted Cox models to standardize the comparisons with the conventional myocarditis group. Also, medical management after hospital discharge was longitudinally assessed using generalized estimated equation models.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n In total, 4635 individuals were hospitalized for myocarditis: 558 with postvaccine myocarditis, 298 with post\u2013COVID-19 myocarditis, and 3779 with conventional myocarditis. Patients with postvaccine myocarditis were younger than those with post\u2013COVID-19 and conventional myocarditis (mean [SD] age of 25.9 [8.6], 31.0 [10.9], and 28.3 [9.4] years, respectively) and were more frequently men (84%, 67%, and 79%). Patients with postvaccine myocarditis had a lower standardized incidence of the composite clinical outcome than those with conventional myocarditis (32\/558 vs 497\/3779 events; weighted hazard ratio, 0.55 [95% CI, 0.36-0.86]), whereas individuals with post\u2013COVID-19 myocarditis had similar results (36\/298 events; weighted hazard ratio, 1.04 [95% CI, 0.70-1.52]). The standardized frequency of medical procedures and drugs prescribed in patients with postvaccine myocarditis or post\u2013COVID-19 myocarditis followed a similar trend in the 18 months following hospital discharge to that of patients with conventional myocarditis.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Patients with post\u2013COVID-19 mRNA vaccination myocarditis, contrary to those with post\u2013COVID-19 myocarditis, show a lower frequency of cardiovascular complications than those with conventional myocarditis at 18 months. However, affected patients, mainly healthy young men, may require medical management up to several months after hospital discharge.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2024.16380","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T15:30:35Z","timestamp":1724686235000},"page":"1367","source":"Crossref","is-referenced-by-count":52,"title":["Long-Term Prognosis of Patients With Myocarditis Attributed to COVID-19 mRNA Vaccination, SARS-CoV-2 Infection, or Conventional Etiologies"],"prefix":"10.1001","volume":"332","author":[{"given":"Laura","family":"Semenzato","sequence":"first","affiliation":[{"name":"EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products and the French National Health Insurance"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Le Vu","sequence":"additional","affiliation":[{"name":"EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products and the French National Health Insurance"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie","family":"Botton","sequence":"additional","affiliation":[{"name":"EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products and the French National Health Insurance"},{"name":"University Paris-Saclay, Facult\u00e9 de pharmacie, Orsay, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Bertrand","sequence":"additional","affiliation":[{"name":"EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products and the French National Health Insurance"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Joelle","family":"Jabagi","sequence":"additional","affiliation":[{"name":"EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products and the French National Health Insurance"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Drouin","sequence":"additional","affiliation":[{"name":"EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products and the French National Health Insurance"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Cuenot","sequence":"additional","affiliation":[{"name":"EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products and the French National Health Insurance"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Zores","sequence":"additional","affiliation":[{"name":"Cardiologist, Specialized Medical Group, Strasbourg, France"},{"name":"Centre Ellipse, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Dray-Spira","sequence":"additional","affiliation":[{"name":"EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products and the French National Health Insurance"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Weill","sequence":"additional","affiliation":[{"name":"EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products and the French National Health Insurance"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Zureik","sequence":"additional","affiliation":[{"name":"EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products and the French National Health Insurance"},{"name":"University Paris-Saclay, UVSQ, University Paris-Sud, Inserm, Anti-infective evasion and Pharmacoepidemiology Unit\/Team, CESP, Montigny le Bretonneux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"joi240100r2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41541-024-00893-1","article-title":"Myocarditis associated with COVID-19 vaccination.","volume":"9","author":"Buoninfante","year":"2024","journal-title":"NPJ Vaccines"},{"issue":"1","key":"joi240100r3","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1038\/s41467-022-31401-5","article-title":"Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines.","volume":"13","author":"Le Vu","year":"2022","journal-title":"Nat Commun"},{"issue":"10","key":"joi240100r4","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1038\/s41591-022-02000-0","article-title":"Long-term cardiac pathology in individuals with mild initial COVID-19 illness.","volume":"28","author":"Puntmann","year":"2022","journal-title":"Nat Med"},{"issue":"3","key":"joi240100r5","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41591-022-01689-3","article-title":"Long-term cardiovascular outcomes of COVID-19.","volume":"28","author":"Xie","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"joi240100r6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2021-000104","article-title":"Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study.","volume":"1","author":"Bouillon","year":"2022","journal-title":"BMJ Med"},{"key":"joi240100r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2023.100325","article-title":"Benefit-risk assessment of Covid-19 vaccine, MRNA (MRNA-1273) for males age 18-64 years.","volume":"14","author":"Yogurtcu","year":"2023","journal-title":"Vaccine X"},{"issue":"4","key":"joi240100r8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1001\/jama.2021.24110","article-title":"Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021.","volume":"327","author":"Oster","year":"2022","journal-title":"JAMA"},{"issue":"11","key":"joi240100r9","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/S2352-4642(22)00244-9","article-title":"Outcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance study.","volume":"6","author":"Kracalik","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"issue":"5","key":"joi240100r10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.55729\/2000-9666.1229","article-title":"Covid- 19 vaccine-induced myocarditis.","volume":"13","author":"Munjal","year":"2023","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"joi240100r11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069445","article-title":"Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.","volume":"378","author":"Pillay","year":"2022","journal-title":"BMJ"},{"issue":"1","key":"joi240100r12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2022-000373","article-title":"Clinical outcomes of myocarditis after SARS-CoV-2 mRNA vaccination in four Nordic countries: population based cohort study.","volume":"2","author":"Husby","year":"2023","journal-title":"BMJ Med"},{"issue":"4","key":"joi240100r13","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/jama.2017.21269","article-title":"Association of hysteroscopic vs laparoscopic sterilization with procedural, gynecological, and medical outcomes.","volume":"319","author":"Bouillon","year":"2018","journal-title":"JAMA"},{"issue":"11","key":"joi240100r14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.42006","article-title":"COVID-19 hospitalization in solid organ transplant recipients on immunosuppressive therapy.","volume":"6","author":"Kolla","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"joi240100r15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/jama.2021.21699","article-title":"Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in people aged 75 years or older.","volume":"327","author":"Jabagi","year":"2022","journal-title":"JAMA"},{"issue":"2","key":"joi240100r16","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1001\/jamaophthalmol.2020.5594","article-title":"Intravitreal anti-vascular endothelial growth factor use in France during the coronavirus disease 2019 pandemic.","volume":"139","author":"Billioti de Gage","year":"2021","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"joi240100r18","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1097\/01.EDE.0000081989.82616.7d","article-title":"Marginal structural models as a tool for standardization.","volume":"14","author":"Sato","year":"2003","journal-title":"Epidemiology"},{"issue":"30","key":"joi240100r19","doi-asserted-by":"publisher","first-page":"5642","DOI":"10.1002\/sim.7084","article-title":"Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis.","volume":"35","author":"Austin","year":"2016","journal-title":"Stat Med"},{"key":"joi240100r20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ahj.2023.11.006","article-title":"Clinical course and follow-up of pediatric patients with COVID-19 vaccine-associated myocarditis compared to non-vaccine-associated myocarditis within the prospective multicenter registry-\u201cMYKKE\u201d.","volume":"267","author":"Rolfs","year":"2024","journal-title":"Am Heart J"},{"issue":"3","key":"joi240100r21","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.vaccine.2023.12.070","article-title":"Long term follow up and outcomes of Covid-19 vaccine associated myocarditis in Victoria, Australia: a clinical surveillance study.","volume":"42","author":"Shenton","year":"2023","journal-title":"Vaccine"},{"issue":"9","key":"joi240100r22","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.024393","article-title":"Comparison of multisystem inflammatory syndrome in children-related myocarditis, classic viral myocarditis, and COVID-19 vaccine-related myocarditis in children.","volume":"11","author":"Patel","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"joi240100r23","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1161\/CIRCULATIONAHA.123.064772","article-title":"Cardiovascular assessment up to one year after COVID-19 vaccine\u2013associated myocarditis.","volume":"148","author":"Yu","year":"2023","journal-title":"Circulation"},{"key":"joi240100r24","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jpeds.2022.03.032","article-title":"Persistent cardiac magnetic resonance imaging findings in a cohort of adolescents with post-coronavirus disease 2019 mRNA vaccine myopericarditis.","volume":"245","author":"Schauer","year":"2022","journal-title":"J Pediatr"},{"issue":"7","key":"joi240100r25","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1007\/s00431-022-04482-z","article-title":"Follow-up cardiac magnetic resonance in children with vaccine-associated myocarditis.","volume":"181","author":"Hadley","year":"2022","journal-title":"Eur J Pediatr"},{"issue":"11","key":"joi240100r26","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.19240","article-title":"Clinical presentation and outcomes of myocarditis post mRNA vaccination: a meta-analysis and systematic review.","volume":"13","author":"Matta","year":"2021","journal-title":"Cureus"},{"issue":"1","key":"joi240100r27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.120.011492","article-title":"Prognostic impact of late gadolinium enhancement by cardiovascular magnetic resonance in myocarditis: a systematic review and meta-analysis.","volume":"14","author":"Georgiopoulos","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"issue":"Sep","key":"joi240100r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2023.131401","article-title":"Overview of SARS-CoV-2 infection and vaccine associated myocarditis compared to non-COVID-19-associated myocarditis: a systematic review and meta-analysis.","volume":"395","author":"Ishisaka","year":"2024","journal-title":"Int J Cardiol"},{"issue":"5","key":"joi240100r29","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1161\/CIRCULATIONAHA.121.056583","article-title":"Clinically suspected myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: suspected myocarditis after COVID-19 vaccination.","volume":"145","author":"Truong","year":"2022","journal-title":"Circulation"},{"issue":"4","key":"joi240100r30","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1177\/02676591231170480","article-title":"Fulminant myocarditis following SARS-CoV-2 mRNA vaccination rescued with venoarterial ECMO: a report of two cases.","volume":"39","author":"Vila-Olives","year":"2023","journal-title":"Perfusion"},{"issue":"3","key":"joi240100r32","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00392-022-02129-5","article-title":"Autopsy-based histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination.","volume":"112","author":"Schwab","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"joi240100r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2023.101280","article-title":"COVID-19 vaccine-associated myocarditis: analysis of the suspected cases reported to the EudraVigilance and a systematic review of the published literature.","volume":"49","author":"Jaiswal","year":"2023","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"10","key":"joi240100r34","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1161\/CIRCRESAHA.122.321881","article-title":"Vaccination-associated myocarditis and myocardial injury.","volume":"132","author":"Altman","year":"2023","journal-title":"Circ Res"},{"issue":"2","key":"joi240100r36","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/pds.4690","article-title":"Diagnostic accuracy of the International Classification of Diseases, Tenth Revision, codes of heart failure in an administrative database.","volume":"28","author":"Bosco-L\u00e9vy","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"joi240100r37","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/fcp.12326","article-title":"Positive predictive values of peripheral arterial and venous thrombosis codes in French hospital database.","volume":"32","author":"Prat","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"key":"joi240100r17","author":"Leslie","year":"2007"},{"key":"joi240100r35","volume-title":"Mandell, Douglas, and Bennett\u2019s Principles and Practice of Infectious Diseases"},{"key":"joi240100r1","unstructured":"European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 29 November - 2 December 2021. December 3, 2021. Accessed August 2, 2024. https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-29-november-2-december-2021"},{"key":"joi240100r31","doi-asserted-by":"crossref","unstructured":"Terry? KJ, Narducci? D, Moran? B, . Myocarditis in athletes: risk factors and relationship with strenuous exercise.? Sports Med. 2024;54(3):607-621. doi:10.1007\/s40279-023-01969-z38079080","DOI":"10.1007\/s40279-023-01969-z"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2822933\/jama_semenzato_2024_oi_240100_1728667653.15103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T11:13:37Z","timestamp":1729595617000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2822933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":37,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,10,22]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2024.16380","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,22]]}}}